Munich — Baker McKen­zie advi­sed Ariceum Thera­peu­tics (Ariceum) on the successful closing of a EUR 25 million Series A finan­cing round led by EQT Life Scien­ces (form­erly LSP) and Health­Cap, and on the acqui­si­tion of assets from Ipsen Pharma.

Ariceum is a priva­tely held biotech­no­logy company deve­lo­ping a novel, first-in-class radio­phar­maceu­ti­cal product for the diagno­sis and targe­ted radia­tion therapy of certain diffi­cult-to-treat cancers. The company was foun­ded by EQT Life Scien­ces (form­erly LSP) and Health­Cap, which also led the over­sub­scri­bed finan­cing round in which Pureos Bioven­turesalso parti­ci­pa­ted. Ipsen trans­fer­red assets and all rights to them to the company.

“Toge­ther with our client and our team of specia­li­zed corpo­rate, biotech­no­logy and life scien­ces lawy­ers, we succee­ded in secu­ring finan­cing, paving the way for the deve­lo­p­ment of a therapy for pati­ents suffe­ring from certain diffi­cult-to-treat cancers,” commen­ted Julia Braun, LL.M., the lead part­ner on the transaction.

Ariceum is led by a highly expe­ri­en­ced manage­ment team with a strong track record and exper­tise in clini­cal trials, syste­mic radio­the­rapy and radio-phar­maceu­ti­cal deve­lo­p­ment, as well as in the launch and commer­cia­liza­tion of diagno­stic and thera­peu­tic products in a variety of indi­ca­ti­ons worldwide.

Baker McKenzie’s Corporate/M&A and Life Scien­ces team regu­larly advi­ses phar­maceu­ti­cal compa­nies, finan­cial and stra­te­gic inves­tors, and early-stage biotech­no­logy compa­nies on dome­stic and inter­na­tio­nal health­care transactions.

Most recently, Baker McKen­zie advi­sed, among others, Andera Part­ners, Evotec and Fund+ on a EUR 60 million Series B finan­cing of Tubu­lis GmbH, Alle­cra Thera­peu­tics on an exclu­sive license and supply agree­ment with ADVANZ PHARMA, MODAG on a stra­te­gic colla­bo­ra­tion with Teva, Chord Thera­peu­tics on its sale to Merck KGaA, LSP as lead inves­tor in a EUR 20 million Series A equity finan­cing of Inno­va­tive Mole­cu­les, Numab Thera­peu­tics in a CHF 100 million cross-over finan­cing, Cata­lYm in a EUR 50 million Series B finan­cing led by Vesa­lius Capi­tal, Casdin Capi­tal as lead inves­tor in DNA Script’s USD 50 million exten­ded Series B equity finan­cing round, and Chr. Hansen Holding in its acqui­si­tion of Jenne­wein Biotechnology.

Legal advi­sor Ariceum Thera­peu­tics: Baker McKenzie

Lead: Corporate/M&A: Julia Braun, LL.M. (Part­ner, Munich)
Team: Corporate/M&A: Dr. Marcus Meese (Part­ner, Munich), Dr. Katja Heuter­kes (Coun­sel, Munich), Dr. Julia Rossié (Asso­ciate, Munich)
Employ­ment: Dr. Matthias Köhler (Part­ner, Berlin), Felix Arnold, Dr. Harasch Yakubi (both Asso­cia­tes, Berlin), Amelie Czekalla (Asso­ciate, Frankfurt)
IP: Dr. Markus Hecht (Coun­sel, Frankfurt)
Tax: Thomas Gierath (Part­ner, Munich), Vikto­ria Ritter (Asso­ciate, Munich), Jochen Meyer-Burow (Part­ner, Frank­furt), Ariane Schaaf (Coun­sel, Frankfurt)

About Baker McKenzie

Complex busi­ness chal­lenges require a holi­stic response across diffe­rent markets, sectors and juris­dic­tions. Baker McKenzie’s solu­ti­ons for clients are accom­pa­nied by seam­less advice, under­pin­ned by in-depth prac­tice and indus­try know­ledge as well as excel­lent local market insights. In more than 70 offices world­wide, we work with our clients to provide solu­ti­ons for a connec­ted world.

In Germany, around 200 lawy­ers in Berlin, Düssel­dorf, Frankfurt/Main and Munich repre­sent the inte­rests of their clients with proven profes­sio­nal exper­tise and inter­na­tio­nal expe­ri­ence. As one of the leading German law firms, Baker McKen­zie advi­ses natio­nal and inter­na­tio­nal compa­nies and insti­tu­ti­ons in all areas of commer­cial law.